Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
New Blood Test Detects Early-Stage Breast Cáncer With 95% Accuracy and Predicts Recurrence Risk

New Blood Test Detects Early-Stage Breast Cáncer With 95% Accuracy and Predicts Recurrence Risk

November 19, 2026 Health Desk Health

A blood test developed in Israel has distinguished women with early-stage breast cancer from healthy women with 95 percent accuracy, a performance the researchers report held even in dense breast tissue, where mammography most often hides tumors, according to Elonce.

The findings were published in Nature on November 12.

  • The experimental blood test, called EPINUC, detected early-stage breast cancer with 95 percent accuracy and worked regardless of breast density.
  • The same epigenetic signature flagged patients at higher risk of recurrence with 81 percent accuracy, including some classified as low risk by standard criteria.
  • The test remains experimental and has not been validated to replace mammography in symptom-free women.

The work is a liquid biopsy: a test that reads traces tumor cells leave in the bloodstream.

What sets it apart is the target. Conventional liquid biopsies hunt for genetic mutations, which are scarce in early tumors and easy to miss without raising false alarms. This one reads epigenetic marks — the chemical signals that tell a cell which genes to use, and how often. If DNA is the recipe book each cell keeps, epigenetic marks are the notes telling the cell which recipes to follow.

How the test reads dying cells

The technology exploits a natural process. When cells die, they release nucleosomes — segments of DNA wrapped around proteins — into the blood, and cancer cells are no exception. Those fragments carry the epigenetic marks of the tissue they came from.

Israeli Researchers Develop Blood Test with 95% Accuracy for Early Breast Cancer Detection — Azat TV

Using single-molecule microscopy and fluorescent markers that recognize dozens of distinct epigenetic tags, the team mapped changes across millions of nucleosomes. The analysis runs on less than a milliliter of plasma, Infobae reported.

Getting the tumor signatures in the first place required speed. “We recruited twelve women who were scheduled for surgical removal of their tumors,” said Dr. Noa Furth, who worked on the study.

“Once a tumor is removed, there is only a short window of opportunity before its epigenetic marks begin to deteriorate. So as each surgery began, the doctors would alert me. I would quickly carry the tissue sample from the hospital to our laboratory, on ice, and we would begin analyzing it that same day.”

The numbers behind the 95 percent

The researchers tested the method on blood samples from 77 breast cancer patients followed for at least five years at the Mayo Clinic in Florida, alongside samples from 30 healthy women. Artificial intelligence models trained to separate the two groups reached 95 percent accuracy — an AUC of 0.95, per Infobae — for tumors still confined to the breast and measuring at most two centimeters.

Instagram

Performance held at stage T1, the earliest stage measured, and did not vary with breast density, Infobae reported. The team later expanded to 188 patient samples with the Sheba and Kaplan medical centers, and Shema said the results stayed consistent across breast cancer subtypes, according to Minuto30.

“Cancer screening studies save lives,” Shema said. “Periodic mammograms reduce the risk of dying from this disease by 22 percent, but the denser the breast tissue, the easier it is for a tumor to hide in the image. Our blood test showed solid diagnostic performance regardless of breast density.”

The aggressive cells that hide inside tumors

Even when breast cancer is caught early and treatment appears successful, the disease returns in 20 to 40 percent of cases. One explanation is that not all cells in a tumor behave alike: treatment may kill most of the mass and leave behind a rare population capable of restarting it.

New Blood Test Detects Early-Stage Breast Cáncer With 95% Accuracy and Predicts Recurrence Risk
Photo: infobae.com

The study found that even tumors classified as low-aggressiveness — including luminal cancers, generally tied to a better prognosis — can harbor a small population of highly invasive cells with a distinct epigenetic signature, Infobae reported.

The more that signature showed up in a patient’s blood, the higher the risk of recurrence. Combined with other epigenetic markers, it distinguished women whose cancer returned during follow-up from those who stayed disease-free with 81 percent accuracy.

Infobae reported a further comparison: against OncotypeDX, a standard genomic test for recurrence risk in hormone-driven breast cancer, EPINUC showed greater discrimination in the cohorts studied. The test even flagged recurrence risk in patients considered low risk by conventional criteria.

Why early detection changes the odds

The survival figures explain the stakes. When breast cancer is confined to the breast, five-year survival is about 99.6 percent. It falls to 86.6 percent once the disease reaches nearby tissue or lymph nodes, and to 32.9 percent at distant sites.

The same epigenetic approach showed promise earlier: a 2022 study by the group detected early-stage colorectal and pancreatic cancers in blood samples.

What stands between the test and the clinic

The test is experimental. It has not been approved to replace mammography or standard diagnostic methods, and it must be validated in larger prospective trials before its value for screening symptom-free women can be judged. The current study is retrospective, Infobae noted.

New Blood Test Detects Early-Stage Breast Cáncer With 95% Accuracy and Predicts Recurrence Risk
Photo: infobae.com

Looking ahead, the team aims to move beyond prediction: finding treatments that strip cancer cells of their epigenetic flexibility, and even pushing already-aggressive cells toward less dangerous behavior. The next step, per Infobae, is confirming whether the test improves diagnosis and identifies women at risk of relapse in larger, prospective studies.

For now, the strongest fact in the study is the one it started from: caught while confined to the breast, breast cancer has a five-year survival of approximately 99.6 percent.

The findings appeared in Nature, a British weekly scientific journal founded in the autumn of 1869 by Norman Lockyer and Alexander MacMillan as a public forum for scientific innovations.

Fewer than 8 percent of submitted papers are accepted for publication, and the journal carries one of the highest impact factors among multidisciplinary science journals, at 50.5 according to the 2022 Journal Citation Reports. In 2007, together with Science, it received the Prince of Asturias Award for Communications and Humanity.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: New Blood-Based RNA Test Detects Precancerous Ovarian Lesions With High Accuracy

More on Blood Test: Mayo Clinic Study: Blood Test Predicts Cognitive Impairment Risk 5-10 Years Ahead

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

More on this

  • Cdiscount Lowers Refurbished iPhone 15 to 389.99 Euros for Black Friday
  • Low-Dose CT Screening Tied to Earlier Stage, Improved Survival in Small Cell Lung Cancer
  • Jessie J Returns to Instagram After Breast Reconstruction Surgery (newsdirectory3.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service